Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Trial Profile

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Mosunetuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Tocilizumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisone; Rituximab; Vincristine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 06 Feb 2019 Planned End Date changed from 28 Sep 2023 to 18 Jun 2022.
    • 06 Feb 2019 Planned primary completion date changed from 30 Apr 2023 to 18 Jun 2022.
    • 27 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top